Stereotaxis, Inc. Common Stock (STXS) Stock
AMEX · STXS
1.27
Fundamentals
Market cap
$130.26M
Price / Earnings ratio
-5.5x
Price / Sales ratio
4.3x
Price / Book ratio
10.6x
Return on assets
-48.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Stereotaxis Q2 Earnings Call Highlights
NeutralSTXSAugust 12, 2026
MarketBeatNeutral
Stereotaxis Q2 Earnings Call Highlights
STXS

Zacks Investment Research
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
NeutralSTXSAugust 11, 2026
Zacks Investment ResearchNeutral
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
STXS

MarketBeat
Stereotaxis Q1 Earnings Call Highlights
NeutralSTXSMay 16, 2026
MarketBeatNeutral
Stereotaxis Q1 Earnings Call Highlights
STXS

Zacks Investment Research
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
NeutralSTXSMay 12, 2026
Zacks Investment ResearchNeutral
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
STXS
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
39M26M13M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
63M41M21M0
Revenue to Profit
2025$32.4M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-21.6M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
Stereotaxis Q2 Earnings Call Highlights
NeutralSTXSAugust 12, 2026
MarketBeatNeutral
Stereotaxis Q2 Earnings Call Highlights
STXS

Zacks Investment Research
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
NeutralSTXSAugust 11, 2026
Zacks Investment ResearchNeutral
Stereotaxis Inc. (STXS) Reports Q2 Loss, Lags Revenue Estimates
STXS

MarketBeat
Stereotaxis Q1 Earnings Call Highlights
NeutralSTXSMay 16, 2026
MarketBeatNeutral
Stereotaxis Q1 Earnings Call Highlights
STXS

Zacks Investment Research
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
NeutralSTXSMay 12, 2026
Zacks Investment ResearchNeutral
Stereotaxis Inc. (STXS) Reports Q1 Loss, Lags Revenue Estimates
STXS

Zacks Investment Research
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
NeutralSTXSApril 23, 2026
Zacks Investment ResearchNeutral
Stereotaxis Stock Up on First U.S. MAGiC Procedures Post Approval
STXS

Zacks Investment Research
STXS to Acquire Robocath to Lead in Endovascular Robotics Market
NeutralSTXSApril 17, 2026
Zacks Investment ResearchNeutral
STXS to Acquire Robocath to Lead in Endovascular Robotics Market
STXS

Zacks Investment Research
STXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery
NeutralSTXSApril 7, 2026
Zacks Investment ResearchNeutral
STXS Gains on FDA Nod for Synchrony System, Expands Digital Surgery
STXS

Zacks Investment Research
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
NeutralSTXSMarch 9, 2026
Zacks Investment ResearchNeutral
Stereotaxis Inc. (STXS) Reports Q4 Loss, Lags Revenue Estimates
STXS

MarketBeat
3 Underrated Robotics Stocks Poised for Huge Gains
NeutralSTXSDecember 15, 2025
MarketBeatNeutral
3 Underrated Robotics Stocks Poised for Huge Gains
STXS

Zacks Investment Research
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025
NeutralSTXSMarch 26, 2025
Zacks Investment ResearchNeutral
3 Promising Surgical Robotics Stocks to Keep an Eye on in 2025
STXS
About Stereotaxis, Inc. Common Stock
No description available.
SectorHealthcare
IndustryMedical Instruments & Supplies
Employees131
CEODr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A.
IPO DateAug 12, 2004
HeadquartersSaint Louis, MO
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. David Leo Fischel C.A.I.A., C.F.A., C.P.A., M.B.A. | CEO & Chairman | 1987 |
| Ms. Kimberly R. Peery CPA | Chief Financial Officer | 1969 |
| Mr. Keith Galloway | Vice President of Operations | — |
| Ms. Patricia S. Williams Esq. | General Counsel & Secretary | 1967 |
Fundamentals
Valuation
Market cap$130.26M
Price-to-sales ratio4.30
Price-to-book value10.56
Price-earnings ratio-5.50
Return on Equity-258.00%
Return on Sales-70.00%
Return on Assets-48.00%
PEG ratio1.31
Earnings Per Share
Earnings Per Share$-0.24
Income Statement
Average volume514,534
EBITDA$-20.10M
1 year high (52w)$3.59
1 year low (52w)$1.24
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$3.00
Est return
130.77%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.7 | +8.1 | -3.5 | +3.3 | ||||||||
| 2022 | -14.4 | -15.5 | -19.3 | -32.6 | -19.9 | -4.7 | +13.0 | -1.4 | -13.0 | +4.5 | +25.9 | -12.7 |
| 2023 | +3.8 | +15.9 | -20.6 | -16.2 | +29.0 | -32.6 | +0.6 | +14.1 | -13.2 | -3.2 | +10.0 | -1.1 |
| 2024 | +8.0 | +32.9 | -3.3 | -8.9 | -19.9 | -4.2 | +13.0 | +21.8 | -8.9 | +2.6 | +23.2 | -6.2 |
| 2025 | +5.7 | -13.1 | -9.3 | +17.0 | +5.4 | -4.9 | +6.6 | +29.7 | +14.8 | -7.3 | -11.5 | -1.7 |
| 2026 | -5.6 | -2.3 | -17.1 | +1.1 | +2.6 | -11.3 | -28.8 | +8.3 | -5.1 |



